Savara Inc. Stock
€1.97
Your prediction
Savara Inc. Stock
Pros and Cons of Savara Inc. in the next few years
Pros
Cons
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | 0.510% | 3.158% | 5.376% | -56.637% | -33.784% | 11.840% | 9.497% |
| Rockwell Medical Inc. | -2.950% | 17.880% | 12.905% | -50.694% | -54.216% | -23.719% | -94.976% |
| Pacira Pharmaceuticals | -1.040% | -2.551% | -7.282% | -1.036% | 3.243% | -63.962% | -60.373% |
| Twist Bioscience Corp | -0.830% | -5.602% | 3.891% | -41.431% | -31.096% | -25.243% | -32.091% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Savara Inc. (symbol: MSTX) operates within the pharmaceuticals sector, focusing on developing therapies for rare respiratory diseases. A financial review of Savara reveals a complex picture marked by significant challenges and a few commendable aspects. Overall, while the company's aim to address unmet medical needs is admirable, the financials highlight a precarious situation that could be concerning for investors.
Strong Market Capitalization: Savara boasts a market capitalization of approximately $649.9 million. This metric indicates a certain level of investor confidence and interest in the company, suggesting potential for further growth or development in its product pipeline.
Book Value: The book value per share stands at $0.882, which may suggest that the stock is trading under its intrinsic value. This can be attractive for value-oriented investors who believe that the stock price inadequately reflects the company's underlying assets.
News
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On May 21, 2025
Savara Announces Participation in Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and